Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CSO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,460 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 339,030 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 310,460 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 71,487 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 71,487 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT II | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,962 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,962 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust for Chldn. | 180,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 180,000 F1: As investment trustee of trusts for the benefit of the reporting person's children. |
| Common StockSEC Table I · non-derivative | Indirectby 2024 GRAT II | 101,988 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 101,988 |
| Common StockSEC Table I · non-derivative | Indirectby Children | 56,048 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 56,048 |
Filing footnotes · ownership attribution and instrument terms
F1: As investment trustee of trusts for the benefit of the reporting person's children.
F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 150,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 753,316 Read SEC document |
| February 19, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 150,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by 2018 GRAT Disclosed balance after: 249,278 Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 94,048 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · derivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,048 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 150,000 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 94,048 underlying shares, the stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · derivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,048 Underlying: Common Stock · 150,000 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 150,000 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 94,048 underlying shares, the stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 118,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 602,594 Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 118,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 48,192 | $377.31 | $18,183,323.52 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,993 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 94,048 | $16.80 | $1,580,006.40 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 76,863 | $377.31 | $29,001,178.53 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,137 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 150,000 | $16.80 | $2,520,000.00 |
DisclosureSEC source: 0001237899-18-000024 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 129,013 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · derivative · entry 27 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,013 Underlying: Common Stock · 129,013 shares Expires 2028-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 16, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 24 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 483,601 Read SEC document |
| November 01, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 24,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2016 GRAT Disclosed balance after: 0 Read SEC document |
| August 22, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 3,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 23 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 484,777 Read SEC document |
| August 21, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 22 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 487,988 Read SEC document |
| August 21, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 03, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 101,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 21 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 487,141 Read SEC document |
| August 03, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 101,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2017 GRAT Disclosed balance after: 75,036 Read SEC document |
| July 24, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 299,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 20 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 385,954 Read SEC document |
| July 24, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 299,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2016 GRAT Disclosed balance after: 24,643 Read SEC document |
| February 16, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 25 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2018 GRAT Disclosed balance after: 400,000 Read SEC document |
| February 16, 2018 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 19 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 86,820 Read SEC document |
| December 19, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 242,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 18 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 486,820 Read SEC document |
| December 19, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 242,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 257,850 | $386.90 | $99,762,165.00 |
DisclosureSEC source: 0001237899-17-000034 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,762 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 14, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 89,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 17 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 244,670 Read SEC document |
| December 14, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 89,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,847 Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 195,438 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001237899-17-000032 · edgardoc.xml · derivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,438 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 95,050 | $385.08 | $36,601,854.00 |
DisclosureSEC source: 0001237899-17-000032 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,612 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 11,124 | $385.08 | $4,283,629.92 |
DisclosureSEC source: 0001237899-17-000032 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 195,438 | $21.92 | $4,284,000.96 |
DisclosureSEC source: 0001237899-17-000032 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 139,474 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000032 · edgardoc.xml · derivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,474 Underlying: Common Stock · 139,474 shares Expires 2027-12-12 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 17, 2017 Filed Feb 8, 2018 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-007629 · a5.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,609 Read SEC document |
| August 03, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 176,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 16 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 155,406 Read SEC document |
| August 03, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 176,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2017 GRAT Disclosed balance after: 176,223 Read SEC document |
| July 21, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 176,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 15 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 331,629 Read SEC document |
| July 21, 2017 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 176,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By 2016 GRAT Disclosed balance after: 323,777 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 64,058 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 64,594 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,130 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,800 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 66,871 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 146,815 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · derivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,815 Underlying: Common Stock · 146,815 shares Expires 2026-12-16 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 89,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 14 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 159,324 Read SEC document |
| December 16, 2016 Filed Dec 14, 2018 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 89,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 195,079 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · derivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,079 shares Expires 2016-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 95,223 | $380.09 | $36,193,310.07 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,348 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 10,429 | $380.09 | $3,963,958.61 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,571 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 195,079 | $20.32 | $3,964,005.28 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2016 Filed Dec 19, 2016 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 67,976 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.